Skip to content

Educational Intervention to Adopt SLT as First-Line Glaucoma Treatment

An Educational Intervention to Increase Adoption of Selective Laser Trabeculoplasty as First-Line Treatment for Glaucoma

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03365778
Enrollment
86
Registered
2017-12-07
Start date
2017-10-23
Completion date
2019-12-31
Last updated
2020-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Open-angle Glaucoma

Keywords

educational intervention, SLT, selective laser trabeculoplasty, POAG, eye drops, Primary Open Angle Glaucoma

Brief summary

The purpose of this study is to develop an educational program that will help improve the patients' understanding of what laser treatment is, how it might be beneficial to them, and why it should be the first eye pressure lowering glaucoma treatment to consider before the use of glaucoma eye drops.

Detailed description

Glaucoma is a disease characterized by optic nerve damage, visual field defects, elevated intraocular pressure (IOP) and progressive vision loss. More than 3 million Americans have glaucoma and more than 150,000 are blind as a result. Regular use of glaucoma medications can usually lower intraocular pressure (IOP), prevent disease progression, preserve vision and prevent blindness. However, many people with glaucoma do not always use their medication as directed, with about one-third to one-half of patients with glaucoma not taking their drops as often as necessary, or have difficulty putting in the drops. There are also numerous local side effects from using glaucoma eye drops including red eyes, blurry vision and dry eye symptoms. Systemic side effects from eye drops range from triggering asthma, to lethargy and depression. Selective laser trabeculoplasty (SLT) has been used safely and effectively for the treatment of elevated IOP in patients with open angle glaucoma for more than 20 years. SLT may result in mild and temporary IOP elevation, but this is a small risk and rarely significant. Other side effects include blurred vison and inflammation of the cornea (front, clear part of the eye), but they are extremely rare. The purpose of this study is to develop an educational program that will help improve the patients' understanding of what laser treatment is, how it might be beneficial to them, and why it should be considered as first glaucoma treatment before the use of glaucoma eye drops.

Interventions

Patients will respond to 5 questions regarding selective laser trabeculoplasty (SLT) versus topical medication to lower eye pressure. Then they will receive educational materials including 20 printed slides and view a 3 minute video on safety and efficacy of SLT. If patients agree to SLT, assistance in scheduling will be provided.

OTHERUsual Care

Patients will respond to 5 questions regarding selective laser trabeculoplasty (SLT) versus topical medication to lower eye pressure. No other guidance will be provided.

OTHEROphthalmologist Educational Intervention

Responses to online survey regarding beliefs and attitudes towards selective laser trabeculoplasty (SLT) before and after educational slide presentation were recorded and compared between physician specialty groups.

Sponsors

Wills Eye
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Intervention model description

Selective Laser Trabeculoplasty (SLT) Educational Intervention group (n=20) or Usual Care group (n=20). Knowledge, beliefs, barriers, and attitudes about SLT vs. medication as first line treatment of glaucoma will be assessed in both groups. To evaluate barriers for widespread adoption of this procedure, we assessed beliefs and attitudes of ophthalmologists regarding SLT. We developed an educational slide presentation targeted at physicians to increase consideration of SLT earlier in glaucoma treatment paradigm.

Eligibility

Sex/Gender
ALL
Age
40 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* patients between 40 and 90 years of age * high-risk ocular hypertension, primary open-angle glaucoma, or pseudo-exfoliation glaucoma * currently treated with at least one glaucoma eye drop with stable intraocular pressure

Exclusion criteria

* previous laser trabeculoplasty * previous glaucoma surgery

Design outcomes

Primary

MeasureTime frameDescription
Completion of Selective Laser Trabeculoplasty (SLT)1 hourPercentage of patients who elect the Selective Laser Trabeculoplasty (SLT), as treatment for lowering eye pressure, compared between a group receiving SLT Educational Intervention and a Usual Care group. Follow-up eye examinations will be screened for a 6-month period to assess number of completed SLTs.
Measure Educational Effects of Selective Laser Trabeculoplasty (SLT)1 hourAttitudes were assessed in the Patient Educational Intervention group before and immediately following intervention to determine how receptive they were regarding Selective Laser Trabeculoplasty (SLT) as a therapy to lowering eye pressure as compared to the more common therapy of daily eye drops.

Secondary

MeasureTime frameDescription
Measure Educational Effects of Selective Laser Trabeculoplasty (SLT) Among Ophthalmologists30 minutesTo evaluate barriers for widespread adoption of selective laser trabeculoplasty (SLT) as first line treatment of high eye pressure, we assessed the beliefs and attitudes of ophthalmologists regarding SLT. An educational slide presentation and survey targeted physicians to increase awareness and consideration of SLT earlier in the glaucoma treatment paradigm. Number of respondents who currently offer laser treatment for newly diagnosed glaucoma patients.

Countries

United States

Participant flow

Participants by arm

ArmCount
Patient Educational Intervention Group
Patients receive educational materials regarding selective laser trabeculoplasty (SLT) versus topical medication (ophthalmic eye drops) to lower eye pressure. Educational intervention: Patients will respond to 5 questions regarding selective laser trabeculoplasty (SLT) versus topical medication to lower eye pressure. Then they will receive educational materials including 20 printed slides and view a 3 minute video on safety and efficacy of SLT. If patients agree to SLT, assistance in scheduling will be provided.
16
Usual Care Group
Patients receive standard of care. Usual care: Patients will respond to 5 questions regarding selective laser trabeculoplasty (SLT) versus topical medication to lower eye pressure. No other guidance will be provided.
17
Ophthalmologist Educational Intervention Group
General ophthalmologists, ophthalmology residents, and glaucoma specialists in the Wills Eye Hospital physician contact database received online survey and educational slide presentation regarding selective laser trabeculoplasty (SLT). No other personal information i.e. age, gender, ethnicity, race was provided by these participants.
53
Total86

Baseline characteristics

CharacteristicTotalPatient Educational Intervention GroupUsual Care GroupOphthalmologist Educational Intervention Group
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
17 Participants8 Participants9 Participants
Age, Categorical
Between 18 and 65 years
16 Participants8 Participants8 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants1 Participants1 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
23 Participants9 Participants14 Participants0 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
61 Participants6 Participants2 Participants53 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
1 Participants1 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
18 Participants5 Participants13 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
60 Participants5 Participants2 Participants53 Participants
Race (NIH/OMB)
White
7 Participants5 Participants2 Participants0 Participants
Region of Enrollment
United States
86 participants16 participants17 participants53 participants
Sex: Female, Male
Female
15 Participants8 Participants7 Participants
Sex: Female, Male
Male
18 Participants8 Participants10 Participants
Type of Ophthalmologist
General ophthalmologists
26 Participants0 Participants0 Participants26 Participants
Type of Ophthalmologist
Glaucoma Specialists
22 Participants0 Participants0 Participants22 Participants
Type of Ophthalmologist
Ophthalmology Residents
5 Participants0 Participants0 Participants5 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 160 / 170 / 53
other
Total, other adverse events
0 / 160 / 170 / 53
serious
Total, serious adverse events
0 / 160 / 170 / 53

Outcome results

Primary

Completion of Selective Laser Trabeculoplasty (SLT)

Percentage of patients who elect the Selective Laser Trabeculoplasty (SLT), as treatment for lowering eye pressure, compared between a group receiving SLT Educational Intervention and a Usual Care group. Follow-up eye examinations will be screened for a 6-month period to assess number of completed SLTs.

Time frame: 1 hour

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Educational Intervention GroupCompletion of Selective Laser Trabeculoplasty (SLT)10 Participants
Usual Care GroupCompletion of Selective Laser Trabeculoplasty (SLT)6 Participants
Primary

Measure Educational Effects of Selective Laser Trabeculoplasty (SLT)

Attitudes were assessed in the Patient Educational Intervention group before and immediately following intervention to determine how receptive they were regarding Selective Laser Trabeculoplasty (SLT) as a therapy to lowering eye pressure as compared to the more common therapy of daily eye drops.

Time frame: 1 hour

Population: Usual Care group not included since they did not receive education intervention.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Educational Intervention GroupMeasure Educational Effects of Selective Laser Trabeculoplasty (SLT)Post-Intervention Yes12 Participants
Educational Intervention GroupMeasure Educational Effects of Selective Laser Trabeculoplasty (SLT)Pre-Intervention Yes0 Participants
Usual Care GroupMeasure Educational Effects of Selective Laser Trabeculoplasty (SLT)Pre-Intervention Yes0 Participants
Usual Care GroupMeasure Educational Effects of Selective Laser Trabeculoplasty (SLT)Post-Intervention Yes0 Participants
Secondary

Measure Educational Effects of Selective Laser Trabeculoplasty (SLT) Among Ophthalmologists

To evaluate barriers for widespread adoption of selective laser trabeculoplasty (SLT) as first line treatment of high eye pressure, we assessed the beliefs and attitudes of ophthalmologists regarding SLT. An educational slide presentation and survey targeted physicians to increase awareness and consideration of SLT earlier in the glaucoma treatment paradigm. Number of respondents who currently offer laser treatment for newly diagnosed glaucoma patients.

Time frame: 30 minutes

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Educational Intervention GroupMeasure Educational Effects of Selective Laser Trabeculoplasty (SLT) Among Ophthalmologists45 Participants

Source: ClinicalTrials.gov · Data processed: Feb 15, 2026